Description

S-23 ZPHC — 10 mg (100 tablets × 10 mg)

Pharma-grade S-23 for advanced research applications

S-23 represents one of the most potent selective androgen receptor modulators (SARMs) currently available for research purposes. This compound, chemically designated as (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide, has demonstrated significant anabolic activity in preclinical studies . ZPHC delivers this research compound in a precise 10 mg tablet format, manufactured to pharmaceutical-grade standards with verified purity exceeding 99%.

S-23 exhibits high androgen receptor binding affinity with an inhibitory constant of 1.7 ± 0.2 nm, comparable to dihydrotestosterone . Preclinical investigations have demonstrated that S-23 promotes increases in lean body mass and bone mineral density while reducing fat mass in a dose-dependent manner . The compound functions as a full agonist at the androgen receptor, distinguishing it from partial agonists in the same class .

This research compound displays zero estrogenic activity, meaning no water retention or estrogen-related side effects are associated with its use . This characteristic makes it particularly suitable for research applications requiring a “dry” appearance. However, researchers should note that S-23 suppresses gonadotropin levels (LH and FSH) by greater than 50% at doses exceeding 0.1 mg daily, necessitating appropriate post-cycle protocols .

The 10 mg scored, film-coated tablets allow for precise dose adjustment, including 5 mg split dosing for initial research protocols. Each batch undergoes rigorous quality control testing for purity, heavy metals, and microbiological contamination. The product is packaged in sealed blisters within tamper-evident boxes featuring scratch-code authenticity verification.

Research applications commonly employ S-23 at 5–20 mg daily over 4–6 week periods. Investigators frequently combine S-23 with Cardarine (GW-501516) or RAD-140 for enhanced research outcomes.

Advanced research compound for body composition studies
Pharmaceutical-grade S-23 with verified purity and quality control
Zero estrogenic activity with significant anabolic potential

---

Technical Specifications

---

Research Applications

Preclinical studies have established S-23 as a compound with significant anabolic potential . The systematic review of SARM research indicates positive effects on physical performance and body composition . S-23 demonstrates a strong affinity for the androgen receptor and is associated with notable strength improvements in research settings .

Key Research Characteristics

High Anabolic Activity: S-23 demonstrates potent anabolic effects in preclinical models, with an ED50 of 0.079 mg/d in levator ani muscle tissue .

Tissue Selectivity: The compound shows differential effects on androgenic versus anabolic tissues, with prostate effects observed at ED50 of 0.43 mg/d .

Gonadotropin Suppression: S-23 effectively suppresses LH levels by greater than 50% at doses above 0.1 mg/d, indicating significant HPTA suppression .

Body Composition Effects: Research demonstrates increased lean mass and bone mineral density with concurrent fat mass reduction .

---

Top 10 Frequently Asked Questions

1. What is S-23 and how does it work?

S-23 is a selective androgen receptor modulator (SARM) that binds to androgen receptors with high affinity, functioning as a full agonist . It was originally investigated for potential applications in hormonal male contraception and has demonstrated significant anabolic activity in preclinical studies . S-23 exhibits an inhibitory constant of 1.7 ± 0.2 nm, comparable to dihydrotestosterone .

2. What are the typical research dosages for S-23?

Research protocols commonly employ S-23 at dosages ranging from 5 to 20 mg daily over 4 to 6 week periods . The scored 10 mg tablets allow for precise dose adjustment, including 5 mg split dosing for initial protocols. Preclinical studies have evaluated doses ranging from 0.05 to 0.75 mg/d in animal models .

3. Is post-cycle therapy (PCT) required after S-23 use?

Yes, PCT is considered mandatory following S-23 use . S-23 significantly suppresses gonadotropin levels (LH and FSH) and endogenous testosterone production . Standard PCT protocols typically employ SERMs such as tamoxifen (20 mg/day), clomiphene (25 mg/day), or toremifene (30 mg/day) for 4 weeks . Bloodwork is recommended to determine the appropriate PCT protocol .

4. What are the potential side effects of S-23?

Preclinical studies indicate S-23 is associated with suppression of gonadotropins and testosterone production, decreased prostate size, and potential effects on spermatogenesis . The systematic review of SARMs indicates moderate rates of mild to moderate adverse effects and a low rate of severe adverse effects . Clinical evidence suggests SARMs may present challenges regarding bone health and sexual function due to absence of estrogenic activity .

5. How does S-23 compare to other SARMs like RAD-140?

S-23 is considered one of the most potent SARMs available for research, with strength benefits reported to exceed those of RAD-140 in some comparative analyses . It is often described as producing the most immediate strength-focused results . S-23 is considered more suppressive than many other SARMs and is typically associated with a “dry, dense, hardened” appearance in user reports .

6. What does “zero estrogenic activity” mean for research applications?

S-23 displays no estrogenic activity, meaning it does not convert to estrogen or stimulate estrogen receptors . This characteristic results in no water retention or estrogen-related side effects . While this property is beneficial for certain research objectives, the absence of estrogenic activity may present clinical challenges regarding bone health and sexual function .

7. Can S-23 be stacked with other research compounds?

Research protocols commonly combine S-23 with Cardarine (GW-501516) or RAD-140 for enhanced outcomes. However, stacking multiple compounds is considered to increase suppression and may require more comprehensive PCT protocols . Researchers should exercise caution and ensure appropriate monitoring when employing combination protocols.

8. What quality controls are in place for this product?

ZPHC S-23 is manufactured to pharmaceutical-grade standards with lab-tested purity exceeding 99%. Each batch undergoes testing for heavy metals and microbiological contamination. The product is packaged in sealed blisters within tamper-evident boxes featuring scratch-code authenticity verification. Tracked worldwide shipping is provided.

9. How should S-23 be stored and handled?

S-23 tablets should be stored in a cool, dry place away from direct sunlight. The sealed blister packaging provides protection from moisture and contamination. Only research personnel with appropriate qualifications should handle this compound. Always refer to the product documentation for specific handling instructions.

10. What is the status of S-23 in clinical research?

S-23 has been studied in preclinical animal models for potential applications including hormonal male contraception and body composition research . The compound has shown promising results in terms of muscle and bone effects, tissue selectivity, and favorable pharmacokinetic properties . However, it remains an investigational compound and has not been approved for human therapeutic use. The evidence supporting SARM tissue selectivity over traditional androgens remains incomplete, warranting cautious interpretation and further comparative research .

---

Evidence-Based Research References

Systematic Review Evidence: A systematic review of nine randomized controlled trials including 970 patients demonstrated that SARMs have positive effects on physical performance and body composition, with moderate rates of mild to moderate adverse effects and a low rate of severe adverse effects .

Preclinical Characterization: S-23 has been extensively characterized in preclinical models, demonstrating high androgen receptor binding affinity (inhibitory constant = 1.7 ± 0.2 nm) and full agonist activity .

Tissue Selectivity Analysis: Critical appraisal of SARM evidence indicates that while SARMs demonstrate favorable anabolic-androgenic ratios in preclinical studies, robust evidence supporting their superiority over traditional androgens remains incomplete .

---

Advanced Research Applications

Body Composition Studies

Preclinical research has demonstrated that S-23 increases lean body mass and bone mineral density while reducing fat mass in a dose-dependent manner . The systematic review of SARM research confirms positive effects on physical performance and body composition across multiple studies .

Hormonal Research

S-23 has been investigated for potential applications in hormonal male contraception, demonstrating effective suppression of gonadotropins and spermatogenesis in preclinical models . Following treatment cessation, fertility was fully reversible in research models .

---

Product Features

• Pharmaceutical-grade manufacturing standards

• Lab-tested purity exceeding 99%

• Scored tablets for precise dose adjustment

• Tamper-evident packaging with authenticity verification

• Tracked worldwide shipping

---

Order S-23 ZPHC — 10 mg (100 tablets × 10 mg) for your research applications today

Visit https://anabolicsteroidsonline.shop/ to place your order and access our complete range of research compounds.